Lexaria Featured on NetworkNewsWire

Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) was featured in a NetworkNewsWire article regarding company’s development and out-licenses of its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules.

Lexaria has developed an oral digestion technology, DehydraTECH™, which improves the absorption rates of nicotine, non-steroid anti-inflammatory drugs (NSAIDs), vitamins and cannabinoids, by as much as five to 10 times. The significance of this edible technology is that this improved absorption may translate into lower dosages and shorter treatment regimens.

To read the full article, click here.

Click here to connect with Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) for an Investor Presentation

Source: www.networknewswire.com